To view Pillar Biosciences’ quality management system certificate for ISO 13485:2016 issued November 24, 2017 please click here.


    "Evaluation of a Targeted NGS Panel using Single-Vial Amplification of Candidate Genes in Solid Tumors" AMP Global 2019 poster

    The use of targeted Next Generation Sequencing (NGS) assays for detection of variants with therapeutic, diagnostic and prognostic potential is well established. Recently, the association of variants in genes leading to DNA damage repair deficiency with response to immunotherapy has expanded the utility of NGS panels. We customized a 47-gene panel using single-tube Stem-Loop Inhibition-Mediated Amplification (SLIMampTM) technology (Pillar Biosciences) for detection of informative variants in tumors including, but not limited to, NSCLC, colorectal and pancreatic cancer, GIST, melanomas, gliomas and thyroid tumors. The 24kb panel covered hotspots in most genes and entire CDS in 3 genes with oncogenic potential. Robust performance with minimal DNA input and limited neoplastic material was central to the experimental design.


    “Single-vial Amplification Based NGS with Rapid Turn-Around-Time for Interrogation of Variants in Tumors” Association for Molecular Pathology 2018 Poster

    Fifty-six previously tested FFPE samples harboring 26 different clinically relevant variants present in 9 genes were included in the evaluation. The ONCO/Reveal panel identified actionable alterations, including missense variants and indels in tumors where the input DNA is as low as 2.5ng. The assay can reliably detect variants with 3% MAF in samples with low input DNA. Variant analysis using PiVAT software provides rapid annotation and interpretation of genomic alterations. The simplicity of a single-vial library preparation coupled with a rapid turn-around-time of 3-4 days from sample to answer, allows for viable implementation of SLIMamp technology in molecular laboratories.


    “Automated Primer Design for Single-Tube Multiplex PCR for Tiled Amplicon Resequencing –TP53 Assay Design and Characterization as a Pilot Study” Association for Molecular Pathology 2018 Poster

    We have demonstrated a rapid and robust primer design pipeline using the TP53 oncogene as a model system. The resulting primers were shown to provide uniform coverage across TP53 and sensitive variant detection at FFPE-derived DNA inputs greater than 1 ng. In addition, the platform has been shown to be extensible to very large primer pools.


    "Evaluation of a high-throughput NGS SLIMamp CFTR Assay" Advances in Genome Biology and Technology Personalized Health 2018 Poster

    To improve the robustness, efficiency and cost-effectiveness of cystic fibrosis transmembrane conductance regulator (CFTR) gene assays, we have applied our SLIMamp assay technology to enable up to 384-plex sequencing of the full coding region on a single MiSeq instrument run.

    148 variants were examined across 53 commercial samples with known variants, 47 clinical samples with known positive status and 5 Genome-in-a-Bottle (GIAB) samples.


    "Development and Evaluation of a Lung Cancer Fusion RNA Panel" Next Generation Diagnostics 2018 Poster

    This poster reviews the assay principle behind Pillar Biosciences’ Lung Cancer Fusion RNA Panel, the types of fusions interrogated, and presents results from 40 samples with known fusions from a variety of sources.


    Clinical and biomarker results from Phase I-II study of PI3K inhibitor BYL719 (Apelisib) plus Nab-paclitaxel in HER2-negative Metastatic Breast Cancer

    At the June 2018 American Society for Clinical Oncology conference held in Chicago IL (USA), the Kansas University Medical Center presented a poster describing the biomarker results of a Phase I-II clinical study of an experimental PI3K inhibitor called BYL719 (Apelisib) from Novartis.

    They used the ONCO/Reveal Multi-Cancer Panel from Pillar Biosciences on circulating cell-free DNA as part of their study. More information about this sensitive and efficient enrichment assay can be found here.


    "Application of ONCO/Reveal Lung & Colon Cancer Panel in CRC samples and effect of DNA damage in FFPE samples" AACR 2018 Conference Poster

    Access a poster presented by Jianfeng Xiao, Ph.D. at the April 2018 American Association for Cancer Research (AACR) in Chicago Illinois.

    The poster presents results from over 200 FFPE samples used for evaluating the performance of the Pillar Biosciences’ ONCO/Reveal Lung & Colon Cancer Panel, with a subset of 27 samples selected for further analysis for DNA artifacts and effectiveness of repair.


    A scientific poster presented by Dartmouth Hitchcock Medical Center at the Association for Molecular Pathology 2017

    Access this poster presented by Fran de Abreu, Ph.D. at the recent Association for Molecular Pathology conference in Salt Lake City, UT November 2017.

    The poster presents results from a total of 15 FFPE samples used for evaluating the performance of the Pillar Biosciences’ ONCO/Reveal Solid Tumor Panel, with the amount of genomic DNA input ranging from 17 – 72 ng and a total of 24 samples run on an Illumina MiSeq system using v3 chemistry.

    A median on-target rate of 99.57% and a median mapping rate of 99.11% are reported, with 100% concordance of previously reported results.


    Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2

    This July 2017 PLOS One paper outlines Pillar Biosciences’ method and further development of the SLIMamp™ technology, and also describes the results of full-gene BRCA1 and BRCA2 panel as applied to cell line DNA and remnant human DNA samples.

    Schenk D, Song G, Ke Y, Wang Z (2017) Amplification of overlapping DNA amplicons in a singletube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2. PLOS ONE 12(7): e0181062.

    Read abstract 

    "Evaluation of the Pillar NGS SLIMamp Lung and Colon Hot Spots Panel", a poster presented at the Association for Molecular Pathology 2016 in Charlotte, NC

    This poster was presented at the Association for Molecular Pathology 2016 conference held in Charlotte, NC and compared the performance of the Pillar Biosciences’ Lung and Colon Panel on an Illumina MiSeq™ to the Thermo Fisher Ampliseq™ Cancer Hotspot Panel v2 on the Ion Torrent PGM™.

    15 previously-characterized FFPE samples found a high degree of concordance (90.0%, 27/30 variants), and the Pillar Biosciences’ assay was shown to be highly reproducible at 5 ng and 50 ng input DNA. Allele frequency measurement reproducibility was also evaluated.

    J. Peterson, F. Blumental de Abreu, Z. Wang, W. Wells, G. Tsongalis, “Evaluation of the Pillar NGS SLIMamp Lung and Colon Hot Spots Panel”. Dartmouth-Hitchcock Medical Center, Lebanon, NH; Pillar Biosciences, Natick, MA